WEBVTT 00:00:00.000 --> 00:00:02.140 Welcome back to the Deep Dive, where we take 00:00:02.140 --> 00:00:04.679 the overwhelming, dense stack of information, 00:00:05.019 --> 00:00:07.580 the academic articles, the market reports, the 00:00:07.580 --> 00:00:10.140 proprietary research, and distill it down into 00:00:10.140 --> 00:00:13.199 the most essential, mind -expanding nuggets of 00:00:13.199 --> 00:00:16.719 insight, all custom -tailored just for you, the 00:00:16.719 --> 00:00:19.100 learner. Our goal is always to provide you with 00:00:19.100 --> 00:00:21.370 a high -speed knowledge shortcut. ensuring that 00:00:21.370 --> 00:00:23.449 by the end of our conversation, you don't just 00:00:23.449 --> 00:00:26.190 know about a complex topic, but you truly understand 00:00:26.190 --> 00:00:29.390 its context, its strategic evolution, and its 00:00:29.390 --> 00:00:32.340 global implications for the future. Today, we 00:00:32.340 --> 00:00:34.700 are undertaking a deep dive into a company that 00:00:34.700 --> 00:00:37.000 has not only innovated within its field, but 00:00:37.000 --> 00:00:40.579 has fundamentally redefined how a major chronic 00:00:40.579 --> 00:00:43.320 disease is managed. Dexcom, Inc. Right. For those 00:00:43.320 --> 00:00:44.840 who might not be familiar, this is an American 00:00:44.840 --> 00:00:46.979 healthcare technology company. And they are focused 00:00:46.979 --> 00:00:49.299 squarely on the development, manufacturing, and 00:00:49.299 --> 00:00:51.539 distribution of continuous glucose monitoring, 00:00:51.719 --> 00:00:55.060 or CGM, systems for individuals managing diabetes. 00:00:55.479 --> 00:00:57.640 And our mission today is, I think, a highly strategic 00:00:57.640 --> 00:01:00.420 one. We're going to unpack the company's history, 00:01:00.579 --> 00:01:03.500 charting its technological evolution from, you 00:01:03.500 --> 00:01:05.799 know, the first kind of cumbersome three -day 00:01:05.799 --> 00:01:08.680 sensor systems right up to the most accurate, 00:01:08.859 --> 00:01:11.379 seamlessly interconnected system that's currently 00:01:11.379 --> 00:01:13.420 available. And crucially, we're also going to 00:01:13.420 --> 00:01:15.659 map out the incredibly sophisticated ecosystem 00:01:15.659 --> 00:01:18.739 of partnerships Dexcom has built. A network that 00:01:18.739 --> 00:01:21.859 is absolutely foundational to defining modern 00:01:21.859 --> 00:01:24.540 automated healthcare technology. It's a fascinating 00:01:24.540 --> 00:01:26.439 story. It really is. And when we talked about 00:01:26.439 --> 00:01:28.439 this company, we need to establish context immediately. 00:01:28.640 --> 00:01:31.280 This isn't some nimble startup or a niche player 00:01:31.280 --> 00:01:33.799 anymore. Oh, not at all. This is a multinational 00:01:33.799 --> 00:01:36.879 financial and technological powerhouse founded 00:01:36.879 --> 00:01:40.480 in 1999, headquartered in sunny San Diego. They 00:01:40.480 --> 00:01:43.000 have just built immense scale. And the financials 00:01:43.000 --> 00:01:44.959 really underscore that power, don't they? They 00:01:44.959 --> 00:01:48.239 absolutely do. Looking at 2024 data, they reported, 00:01:48.400 --> 00:01:52.420 what, U .S. $4 .03 billion in revenue? Four billion. 00:01:52.599 --> 00:01:54.680 And to put that into perspective for their operational 00:01:54.680 --> 00:01:57.040 efficiency, they achieved an operating income 00:01:57.040 --> 00:02:00.599 of U .S. $600 million and a net income hitting 00:02:00.599 --> 00:02:04.340 U .S. $576 million. And as of the latest reports, 00:02:04.560 --> 00:02:08.990 they employ over 10 ,300 people globally. But 00:02:08.990 --> 00:02:11.490 I think the real institutional tell is their 00:02:11.490 --> 00:02:14.210 market status. You mean their inclusion in the 00:02:14.210 --> 00:02:16.469 major indices? Exactly. They're components of 00:02:16.469 --> 00:02:18.610 two of the most critical market indices, the 00:02:18.610 --> 00:02:21.990 NASDAQ 100 and the S &P 500. That inclusion in 00:02:21.990 --> 00:02:24.349 those indices is often just overlooked as a financial 00:02:24.349 --> 00:02:27.210 detail, but it speaks volumes about the company's 00:02:27.210 --> 00:02:29.449 stability and influence, doesn't it? It really 00:02:29.449 --> 00:02:31.949 does. I mean, it signifies that their performance 00:02:31.949 --> 00:02:34.289 is considered indicative of the health of the 00:02:34.289 --> 00:02:37.169 entire health tech sector. It establishes Dexcom 00:02:37.169 --> 00:02:40.189 as a bellwether stock. Precisely. When analysts 00:02:40.189 --> 00:02:42.349 want to gauge the investment appetite for medical 00:02:42.349 --> 00:02:45.150 technology, for chronic disease management platforms, 00:02:45.370 --> 00:02:48.650 or even for hardware integration systems, they 00:02:48.650 --> 00:02:51.479 look at Dexcom. So they've matured from a pioneering 00:02:51.479 --> 00:02:54.699 tech firm into a vital foundational piece of 00:02:54.699 --> 00:02:57.120 the general economic and health care landscape. 00:02:57.340 --> 00:02:58.979 That's a perfect way to put it. That sets the 00:02:58.979 --> 00:03:01.539 stage perfectly for our historical dive. So let's 00:03:01.539 --> 00:03:03.419 start at the very beginning with the genesis 00:03:03.419 --> 00:03:06.960 of Dexcom and explore how a 1999 startup grew 00:03:06.960 --> 00:03:09.979 into this multinational giant we see today. The 00:03:09.979 --> 00:03:13.439 founding moment was indeed 1999. The company 00:03:13.439 --> 00:03:16.840 was the vision of five key individuals. Scott 00:03:16.840 --> 00:03:20.789 Glenn. John Byrd. Lauren Onsuki, Ellen Preston, 00:03:20.789 --> 00:03:23.650 and Brett Megergel. And from the outset, their 00:03:23.650 --> 00:03:25.889 mission was pretty singular, right? Remarkably 00:03:25.889 --> 00:03:28.310 singular and focused, developing, manufacturing, 00:03:28.710 --> 00:03:30.830 producing, and distributing continuous glucose 00:03:30.830 --> 00:03:33.009 monitoring systems. They weren't trying to build 00:03:33.009 --> 00:03:34.729 everything. They were trying to master one essential 00:03:34.729 --> 00:03:36.789 technology. And what's particularly compelling 00:03:36.789 --> 00:03:39.370 about their early growth is how quickly they 00:03:39.370 --> 00:03:42.849 solidified their market position and moved to 00:03:42.849 --> 00:03:45.180 gain serious capital. They went public. relatively 00:03:45.180 --> 00:03:48.300 early. They did listing on NASDAQ in 2005 under 00:03:48.300 --> 00:03:51.620 the ticker DXCM. Why was going public so crucial 00:03:51.620 --> 00:03:54.099 at that early stage for a medical device company 00:03:54.099 --> 00:03:56.759 like this? Well, for a company developing hardware 00:03:56.759 --> 00:03:59.879 that requires just immense sustained R &D and, 00:03:59.900 --> 00:04:01.780 you know, medical device trials are famously 00:04:01.780 --> 00:04:04.590 expensive and lengthy. Sure. Accessing the public 00:04:04.590 --> 00:04:06.569 market was critical. It was about raising the 00:04:06.569 --> 00:04:08.909 capital needed to fuel those decade -long development 00:04:08.909 --> 00:04:11.330 cycles. It allowed them to maintain that relentless 00:04:11.330 --> 00:04:13.550 pace of innovation, which is really the defining 00:04:13.550 --> 00:04:16.430 characteristic of their success. And their growing 00:04:16.430 --> 00:04:19.209 influence is measurable through those index inclusions. 00:04:19.980 --> 00:04:22.279 When they became a component of the Nasdaq 100 00:04:22.279 --> 00:04:26.079 in April 2020, taking the place of American Airlines 00:04:26.079 --> 00:04:28.680 Group, of all things. Right. It wasn't just a 00:04:28.680 --> 00:04:31.139 corporate pet on the back. It indicated that 00:04:31.139 --> 00:04:33.819 in the eyes of institutional investors, their 00:04:33.819 --> 00:04:36.740 market cap and stability had elevated them to 00:04:36.740 --> 00:04:39.360 the ranks of major transformative tech companies. 00:04:39.699 --> 00:04:41.500 And of course, their subsequent inclusion in 00:04:41.500 --> 00:04:44.319 the S &P 500 further cemented that status. These 00:04:44.319 --> 00:04:46.160 aren't just vanity metrics. No, they have real 00:04:46.160 --> 00:04:48.660 world impact. They mean that vast pools of investment 00:04:48.660 --> 00:04:51.220 capital. which automatically track these indices, 00:04:51.480 --> 00:04:55.120 are mandated to hold Dexcom stock, which guarantees 00:04:55.120 --> 00:04:57.819 liquidity and institutional stability for their 00:04:57.819 --> 00:05:00.339 continued operations. So let's just revisit those 00:05:00.339 --> 00:05:02.600 2024 numbers you mentioned to underscore what 00:05:02.600 --> 00:05:05.939 this financial stability actually supports. When 00:05:05.939 --> 00:05:09.139 a company reports total assets of U .S. $6 .48 00:05:09.139 --> 00:05:12.899 billion and total equity of U .S. $2 .10 billion, 00:05:13.220 --> 00:05:15.439 we're talking about more than just cash flow. 00:05:15.579 --> 00:05:18.180 This speaks to an immense infrastructure. Exactly. 00:05:18.180 --> 00:05:20.879 And a strong financial foundation supporting 00:05:20.879 --> 00:05:23.220 continuous high -risk research and development. 00:05:23.899 --> 00:05:26.800 That capital allows them to take massive risks 00:05:26.800 --> 00:05:30.019 on revolutionary technologies like developing 00:05:30.019 --> 00:05:32.579 the G7 in partnership with Google, which I'm 00:05:32.579 --> 00:05:34.579 sure we'll get into. Oh, definitely. They aren't 00:05:34.579 --> 00:05:37.060 just iterating on a product. They have the capital 00:05:37.060 --> 00:05:40.300 muscle to attempt to redefine the entire chronic 00:05:40.300 --> 00:05:43.639 care management field. So with that kind of immense 00:05:43.639 --> 00:05:46.600 capital and infrastructure, Dexcom isn't just 00:05:46.600 --> 00:05:48.959 funding R &D in California. They're building 00:05:48.959 --> 00:05:51.560 a globally resilient supply chain. Absolutely. 00:05:51.839 --> 00:05:54.300 And that brings us to their international scale 00:05:54.300 --> 00:05:57.560 and operations. While the company is distinctly 00:05:57.560 --> 00:06:00.220 American in origin, they are truly multinational 00:06:00.220 --> 00:06:02.379 in their manufacturing and distribution. That's 00:06:02.379 --> 00:06:04.500 a great point. The global headquarters and the 00:06:04.500 --> 00:06:06.259 crucial R &D center, you know, the nerve center 00:06:06.259 --> 00:06:08.819 for innovation, logically remain centralized 00:06:08.819 --> 00:06:11.300 in San Diego, California. Right. But the physical 00:06:11.300 --> 00:06:13.899 production footprint is a masterclass in strategic 00:06:13.899 --> 00:06:17.139 global logistics. So where exactly are these 00:06:17.139 --> 00:06:19.839 sophisticated high -tech sensors being produced 00:06:19.839 --> 00:06:22.819 to meet this multibillion -dollar global demand? 00:06:23.180 --> 00:06:26.259 The sources outline a very deliberate, diversified 00:06:26.259 --> 00:06:29.670 manufacturing footprint. They operate state -of 00:06:29.670 --> 00:06:33.329 -the -art facilities in three distinct strategically 00:06:33.329 --> 00:06:36.329 located areas. Domestically, they have a major 00:06:36.329 --> 00:06:38.389 facility in Mesa, Arizona. And internationally? 00:06:38.790 --> 00:06:40.670 Internationally, they have a massive presence 00:06:40.670 --> 00:06:43.550 in Batu Kawan, Malaysia, and a critical European 00:06:43.550 --> 00:06:47.160 hub in Athenry, County Galway, Ireland. That 00:06:47.160 --> 00:06:49.860 geographic spread is essential and it tells a 00:06:49.860 --> 00:06:52.339 very specific story about their strategic thinking. 00:06:52.740 --> 00:06:56.279 Why those locations? What do they get from manufacturing 00:06:56.279 --> 00:06:59.339 in Ireland and Malaysia versus, say, just centralizing 00:06:59.339 --> 00:07:01.660 everything in the U .S.? I think it's threefold. 00:07:01.759 --> 00:07:04.500 It's risk mitigation, labor optimization and 00:07:04.500 --> 00:07:06.639 market access efficiency. OK, break that down 00:07:06.639 --> 00:07:09.540 for us. So Mesa provides proximity and security 00:07:09.540 --> 00:07:12.699 for the North American market. Ireland. Specifically, 00:07:12.839 --> 00:07:15.800 the facility in Athenry offers a fantastic gateway 00:07:15.800 --> 00:07:17.920 into the European Union markets. Right. With 00:07:17.920 --> 00:07:20.519 favorable trade agreements and that skilled labor 00:07:20.519 --> 00:07:23.019 pool. Exactly. Yeah. They understand the complex 00:07:23.019 --> 00:07:25.639 medical device manufacturing standards, the whole 00:07:25.639 --> 00:07:29.379 CE mark environment. And Malaysia. Batu Kawan. 00:07:29.519 --> 00:07:32.139 That sounds like it's positioned for maximum 00:07:32.139 --> 00:07:34.680 global reach. It is. The Malaysian facility is 00:07:34.680 --> 00:07:37.420 a huge hub for serving the expansive Asian markets, 00:07:37.639 --> 00:07:40.339 and it allows them to utilize highly efficient 00:07:40.339 --> 00:07:43.459 global supply chains for raw materials and components 00:07:43.459 --> 00:07:46.060 flowing through that region. So this diversification 00:07:46.060 --> 00:07:48.819 ensures they can maintain production even when 00:07:48.819 --> 00:07:51.100 facing global supply chain disruptions like the 00:07:51.100 --> 00:07:53.560 ones we saw during the pandemic. Exactly. For 00:07:53.560 --> 00:07:55.660 a life -sustaining medical device, resilient 00:07:55.660 --> 00:07:59.629 production isn't a luxury. It's a pain. It demonstrates 00:07:59.629 --> 00:08:02.550 a very mature company that understood early on 00:08:02.550 --> 00:08:05.410 that successful medical device deployment requires 00:08:05.410 --> 00:08:09.069 not just brilliant R &D, but also resilient, 00:08:09.310 --> 00:08:11.870 high -volume manufacturing distributed across 00:08:11.870 --> 00:08:14.410 multiple continents. That's it in a nutshell. 00:08:14.629 --> 00:08:16.509 Okay, let's unpack this. Let's shift our focus 00:08:16.509 --> 00:08:18.569 entirely to the products themselves because the 00:08:18.569 --> 00:08:20.949 speed of innovation here is truly astounding. 00:08:21.089 --> 00:08:23.569 We are going from a three -day device that was, 00:08:23.670 --> 00:08:26.149 you know, cumbersome to one that is now considered 00:08:26.149 --> 00:08:27.800 the most accurate on the market. market in less 00:08:27.800 --> 00:08:30.319 than two decades. This chronological progression 00:08:30.319 --> 00:08:33.379 is really the core story of Dexcom. It illustrates 00:08:33.379 --> 00:08:36.639 a relentless capital -fueled pursuit of user 00:08:36.639 --> 00:08:39.460 experience and clinical accuracy, always focusing 00:08:39.460 --> 00:08:41.960 on reducing the burden of diabetes management. 00:08:42.240 --> 00:08:44.779 And it begins in 2006, right, with the official 00:08:44.779 --> 00:08:47.779 dawn of their CGM technology. After years in 00:08:47.779 --> 00:08:51.360 development, yes. That was the Dexcom STS continuous 00:08:51.360 --> 00:08:54.779 glucose monitoring system. the STS. So what were 00:08:54.779 --> 00:08:56.779 its defining features? And more importantly, 00:08:56.899 --> 00:08:59.139 what was the patient experience like when it 00:08:59.139 --> 00:09:02.220 first got FDA approval? Well, the STS was foundational, 00:09:02.440 --> 00:09:05.539 but it was demanding. Its key feature was the 00:09:05.539 --> 00:09:08.080 three -day sensor lifespan. Just three days? 00:09:08.240 --> 00:09:10.879 Three days. But in clinical terms, this provided 00:09:10.879 --> 00:09:14.240 up to 288 glucose measurements over 24 hours. 00:09:14.740 --> 00:09:17.519 And this was revolutionary because prior to this, 00:09:17.639 --> 00:09:20.039 patients relied almost exclusively on finger 00:09:20.039 --> 00:09:22.850 stick blood glucose testing. A painful, inconvenient, 00:09:23.230 --> 00:09:25.870 and really reactive process. Totally reactive. 00:09:26.169 --> 00:09:28.669 The STS provided continuous trend data for the 00:09:28.669 --> 00:09:31.110 first time for many people. But three days means 00:09:31.110 --> 00:09:33.710 initiating a new sensor every 72 hours. That 00:09:33.710 --> 00:09:35.549 must have been a huge compliance hurdle for people. 00:09:36.090 --> 00:09:38.629 It absolutely was. I mean, while the data was 00:09:38.629 --> 00:09:41.070 invaluable, the frequent sensor changes, the 00:09:41.070 --> 00:09:43.789 warm -up periods, the general sight discomfort, 00:09:44.110 --> 00:09:47.049 it meant adherence was a constant struggle. But 00:09:47.049 --> 00:09:49.409 they knew that. Oh, they understood this limitation 00:09:49.409 --> 00:09:52.929 and immediately iterated. Just one year later, 00:09:53.049 --> 00:09:56.070 in May 2007, they launched the second generation, 00:09:56.230 --> 00:09:58.860 the 7 Continuous Glucose Monitoring System. The 00:09:58.860 --> 00:10:01.340 seven, it seems like a simple name change, but 00:10:01.340 --> 00:10:03.879 it actually represented that huge quality of 00:10:03.879 --> 00:10:06.200 life leap we were talking about. It was critical 00:10:06.200 --> 00:10:08.799 because it directly addressed the major pain 00:10:08.799 --> 00:10:12.830 point of its predecessor. The 7 model enhanced 00:10:12.830 --> 00:10:14.970 overall accuracy, which is always important, 00:10:15.190 --> 00:10:17.649 but the user -facing improvement was massive. 00:10:17.809 --> 00:10:19.710 It had extended the sensor use. Dramatically, 00:10:19.850 --> 00:10:22.149 shifting from three days to a full seven days. 00:10:22.309 --> 00:10:24.289 Doubling the wear time is not a trivial achievement 00:10:24.289 --> 00:10:26.309 in medical engineering. From the patient perspective, 00:10:26.509 --> 00:10:28.549 you're literally halving the frequency of the 00:10:28.549 --> 00:10:30.809 site changes, the setup procedures, the adhesive 00:10:30.809 --> 00:10:33.610 wear and tear. That's a huge qualitative liberation, 00:10:33.929 --> 00:10:36.730 and that's a key insight. The significance of 00:10:36.730 --> 00:10:39.549 those early incremental improvements, like the 00:10:39.549 --> 00:10:42.450 jump from three to seven days, you just can't 00:10:42.450 --> 00:10:45.129 overstate it in terms of improving patient adherence. 00:10:45.210 --> 00:10:47.370 Because if the device is easier to live with... 00:10:47.549 --> 00:10:49.590 people use it more consistently. And that translates 00:10:49.590 --> 00:10:52.629 directly into better long -term A1C levels and 00:10:52.629 --> 00:10:55.590 fewer complications. It made continuous monitoring 00:10:55.590 --> 00:10:58.610 practical for daily living, not just a clinical 00:10:58.610 --> 00:11:00.950 tool. And the refinement continued quickly. By 00:11:00.950 --> 00:11:04.350 February 2009, they secured FDA approval for 00:11:04.350 --> 00:11:07.450 the 7 Plus. Followed by the crucial CE mark in 00:11:07.450 --> 00:11:10.610 November 2009, which opened up that massive European 00:11:10.610 --> 00:11:13.330 market to this seven -day technology. And that 00:11:13.330 --> 00:11:15.909 successful early iteration really set the stage 00:11:15.909 --> 00:11:18.549 for the big technological shift. The G -series. 00:11:18.730 --> 00:11:21.250 This is where the focus moved from merely monitoring 00:11:21.250 --> 00:11:24.190 to connectivity and specialized life -saving 00:11:24.190 --> 00:11:26.870 accuracy. The first G -series device, the G4 00:11:26.870 --> 00:11:29.850 Platinum, arrived in 2012. It got the CE mark 00:11:29.850 --> 00:11:31.929 and initial FDA approval, though it was limited 00:11:31.929 --> 00:11:34.629 to adults 18 and over at first. Right. So what 00:11:34.629 --> 00:11:37.389 made the G4 a platinum -level leap? It was a 00:11:37.389 --> 00:11:39.750 technical advancement focused directly on patient 00:11:39.750 --> 00:11:43.679 safety. The G4 platinum improved hypoglycemic 00:11:43.679 --> 00:11:49.419 accuracy by a remarkable 30%. 30%. Wow. And hypoglycemia, 00:11:49.419 --> 00:11:51.960 or dangerously low blood sugar, that's the most 00:11:51.960 --> 00:11:54.080 immediate and critical life threat for someone 00:11:54.080 --> 00:11:56.700 using insulin. Absolutely. It can lead to confusion, 00:11:56.960 --> 00:11:59.539 seizures, or unconsciousness very, very quickly. 00:11:59.720 --> 00:12:02.379 So improving the device's reliability and accuracy 00:12:02.379 --> 00:12:05.200 in that low glucose range, when the patient is 00:12:05.200 --> 00:12:08.059 most vulnerable, that was a major clinical win. 00:12:08.159 --> 00:12:10.299 It could potentially prevent catastrophic events, 00:12:10.460 --> 00:12:13.299 especially overnight. For sure. And beyond accuracy, 00:12:13.460 --> 00:12:15.779 the device itself was improved. It featured a 00:12:15.779 --> 00:12:18.500 longer transmission range. the first time a color 00:12:18.500 --> 00:12:21.200 LCD screen on the receiver unit, which made the 00:12:21.200 --> 00:12:23.919 data much more readable. That simultaneous focus 00:12:23.919 --> 00:12:26.539 on safety and usability seems to define the G4 00:12:26.539 --> 00:12:29.019 era. It does, and we see rapid expansion on two 00:12:29.019 --> 00:12:31.460 fronts following that launch, clinical capability 00:12:31.460 --> 00:12:34.779 and market scope. In 2014, the G4 Platinum was 00:12:34.779 --> 00:12:37.059 approved for use in younger patients, ages 2 00:12:37.059 --> 00:12:40.039 to 17. A huge deal for parents. Yeah. And then 00:12:40.039 --> 00:12:41.720 came the introduction of seamless connectivity. 00:12:42.350 --> 00:12:45.750 Right. In January 2015, they received FDA approval 00:12:45.750 --> 00:12:48.710 for the G4 Platinum with Share. This wasn't just 00:12:48.710 --> 00:12:51.169 data logging. This was a foundational step toward 00:12:51.169 --> 00:12:53.990 remote care. It enabled the automatic sharing 00:12:53.990 --> 00:12:56.330 of CGM data with up to five other designated 00:12:56.330 --> 00:12:59.289 people using the dedicated Share and Follow smartphone 00:12:59.289 --> 00:13:02.370 apps. That was a monumental change for parents 00:13:02.370 --> 00:13:04.769 of diabetic children. It gave them the ability 00:13:04.769 --> 00:13:07.070 to remotely monitor their child's blood sugar 00:13:07.070 --> 00:13:09.450 levels in real time while they were at school 00:13:09.450 --> 00:13:13.590 or asleep. Reducing anxiety. It essentially turned 00:13:13.590 --> 00:13:16.769 the monitor into an instant remote alert system. 00:13:16.889 --> 00:13:18.990 It was a critical step in turning a personal 00:13:18.990 --> 00:13:21.590 device into a family care tool. But here's where 00:13:21.590 --> 00:13:23.389 it gets really interesting. Because the next 00:13:23.389 --> 00:13:26.929 step, the G5, freed the data entirely from the 00:13:26.929 --> 00:13:29.629 need for the dedicated receiver. The G5 approved 00:13:29.629 --> 00:13:32.929 in August 2015 as a standalone device. So from 00:13:32.929 --> 00:13:35.210 a product engineering standpoint, what was the 00:13:35.210 --> 00:13:37.470 core innovation that allowed this data freedom? 00:13:37.710 --> 00:13:39.509 What did that mean for the patient's pocket? 00:13:39.750 --> 00:13:41.830 The core innovation was the integrated Bluetooth 00:13:41.830 --> 00:13:44.809 radio. They miniaturized and built Bluetooth 00:13:44.809 --> 00:13:47.529 directly into the transmitter unit itself. So 00:13:47.529 --> 00:13:50.039 no separate receiver needed. This meant the G5 00:13:50.039 --> 00:13:52.820 could transmit glucose data directly to a mobile 00:13:52.820 --> 00:13:56.200 device, an iPhone or Android smartphone, without 00:13:56.200 --> 00:13:59.039 the need for the separate standalone Dexcom receiver. 00:13:59.399 --> 00:14:01.580 So the patient could just leave that dedicated 00:14:01.580 --> 00:14:03.639 receiver at home. They went from needing a sensor, 00:14:03.820 --> 00:14:06.080 a transmitter, and a receiver to just needing 00:14:06.080 --> 00:14:08.159 the sensor, transmitter, and the phone they already 00:14:08.159 --> 00:14:10.860 carry. Which is a massive reduction in the mental 00:14:10.860 --> 00:14:13.620 burden and physical bulk of managing the disease. 00:14:13.879 --> 00:14:16.200 It was the transition point. It moved the device. 00:14:16.809 --> 00:14:18.870 From being a necessary medical accessory to a 00:14:18.870 --> 00:14:21.809 true piece of integrated consumer health technology. 00:14:22.149 --> 00:14:24.610 It streamlined the user experience dramatically 00:14:24.610 --> 00:14:28.389 and integrated CGM data directly into the patient's 00:14:28.389 --> 00:14:31.210 existing digital life. And the pace just accelerates 00:14:31.210 --> 00:14:34.009 from there with the G6. By 2018, the G6 gained 00:14:34.009 --> 00:14:36.889 FDA approval and it received a designation that 00:14:36.889 --> 00:14:39.070 sounds, you know, purely bureaucratic, but is 00:14:39.070 --> 00:14:41.110 actually revolutionary. It was designated the 00:14:41.110 --> 00:14:44.110 first fully interoperable continuous glucose 00:14:44.110 --> 00:14:46.669 monitoring system. That designation is called 00:14:46.669 --> 00:14:49.789 ICGM or integrated continuous glucose monitoring. 00:14:50.029 --> 00:14:52.289 Let's spend a moment unpacking why this is so 00:14:52.289 --> 00:14:54.809 revolutionary. What does interoperability actually 00:14:54.809 --> 00:14:58.070 mean here? It's a great question. In this context. 00:14:58.570 --> 00:15:01.110 It means the G6 was designed specifically to 00:15:01.110 --> 00:15:03.950 communicate easily and securely with other medical 00:15:03.950 --> 00:15:06.870 devices made by different companies, primarily 00:15:06.870 --> 00:15:09.289 insulin pumps and automated delivery systems. 00:15:09.490 --> 00:15:11.649 Why was that such a technical and regulatory 00:15:11.649 --> 00:15:13.789 hurdle? Why couldn't they just plug and play 00:15:13.789 --> 00:15:16.230 before the G6? The regulatory environment was 00:15:16.230 --> 00:15:19.649 very protective and for good reason. For safety 00:15:19.649 --> 00:15:22.190 reasons, the FDA traditionally required tight 00:15:22.190 --> 00:15:24.929 proprietary pairings between a sensor and a pump. 00:15:25.110 --> 00:15:27.570 Ah, so you had to use Company A's sensor with 00:15:27.570 --> 00:15:30.690 Company A's pump. Exactly. Achieving the ICGM 00:15:30.690 --> 00:15:33.350 designation meant proving to the FDA that the 00:15:33.350 --> 00:15:36.289 G6's communication protocols were secure, reliable, 00:15:36.649 --> 00:15:38.889 and standardized enough to manage the life -critical 00:15:38.889 --> 00:15:41.269 function of automated insulin delivery, regardless 00:15:41.269 --> 00:15:43.250 of the pump manufacturer on the other end. So 00:15:43.250 --> 00:15:45.570 this was the technical key that truly unlocked 00:15:45.570 --> 00:15:47.649 the closed -loop revolution. Which forms the 00:15:47.649 --> 00:15:49.549 basis of our next section. It was a massive, 00:15:49.610 --> 00:15:51.870 massive deal. And that brings us right up to 00:15:51.870 --> 00:15:54.850 the cutting edge, the G7, which benefited from 00:15:54.850 --> 00:15:57.809 that huge... Google slash Verily partnership. 00:15:58.309 --> 00:16:01.549 Right. The Dexcom G7 was approved by the FDA 00:16:01.549 --> 00:16:05.009 in December 2022. The sources are pretty definitive 00:16:05.009 --> 00:16:07.629 on this. It is identified as the most accurate 00:16:07.629 --> 00:16:10.269 continuous glucose monitoring system currently 00:16:10.269 --> 00:16:12.509 approved in the U .S. for standalone use. And 00:16:12.509 --> 00:16:14.570 the metric for that is ARNARD. ARNARD, yeah. 00:16:15.100 --> 00:16:17.980 Absolute relative difference. And the G7 reportedly 00:16:17.980 --> 00:16:20.740 has one of the lowest MARDS ever achieved, meaning 00:16:20.740 --> 00:16:23.139 its readings are incredibly close to the actual 00:16:23.139 --> 00:16:25.799 broad glucose levels. So even while they're optimizing 00:16:25.799 --> 00:16:28.720 for size and integration, the core function accuracy 00:16:28.720 --> 00:16:31.600 remains their primary competitive driver. Always. 00:16:31.980 --> 00:16:33.500 And finally, we have to talk about the strategic 00:16:33.500 --> 00:16:36.039 shift toward non -prescription access that happened 00:16:36.039 --> 00:16:40.100 this year. The STELO. Yes. In October 2024, Time 00:16:40.100 --> 00:16:42.659 magazine named the Dexcom Stilo over -the -counter 00:16:42.659 --> 00:16:45.000 glucose monitor one of the year's best inventions. 00:16:45.279 --> 00:16:47.440 And the Stilo is perhaps the most significant 00:16:47.440 --> 00:16:49.720 market move since the G5 introduced Bluetooth. 00:16:49.919 --> 00:16:52.639 I would agree. It signals Dexcom's strategic 00:16:52.639 --> 00:16:55.840 intent to pivot, at least partially, toward the 00:16:55.840 --> 00:16:58.240 non -insulin dependent market. It's a move toward 00:16:58.240 --> 00:17:01.480 reaching non -insulin using type 2 patients and 00:17:01.480 --> 00:17:05.420 that, you know. insanely curious consumer segment 00:17:05.420 --> 00:17:08.700 focused on metabolic health optimization. It's 00:17:08.700 --> 00:17:11.839 moving CGM from a clinical necessity to a wellness 00:17:11.839 --> 00:17:14.259 and preventative tool. A huge strategic shift. 00:17:14.519 --> 00:17:16.440 Understanding the technology is only half the 00:17:16.440 --> 00:17:18.859 battle. The other half, the truly brilliant corporate 00:17:18.859 --> 00:17:21.619 strategy, is understanding how Dexcom positioned 00:17:21.619 --> 00:17:24.339 itself not just as a hardware company, but as 00:17:24.339 --> 00:17:26.720 the indispensable data provider, the central 00:17:26.720 --> 00:17:29.660 brain for an entire ecosystem of diabetes management. 00:17:30.059 --> 00:17:32.500 That's the key analytical takeaway. They realized 00:17:32.500 --> 00:17:34.819 early on that the accurate continuous sensor 00:17:34.819 --> 00:17:37.720 data was the most valuable asset, and they needed... 00:17:37.769 --> 00:17:40.130 strategic partners, even competitors in the insulin 00:17:40.130 --> 00:17:42.609 pump space to convert that data into automated 00:17:42.609 --> 00:17:45.150 action. And this idea of expansion and strategic 00:17:45.150 --> 00:17:47.890 growth can be traced way back to their earliest 00:17:47.890 --> 00:17:50.730 agreements. Back in 2008, they were already forging 00:17:50.730 --> 00:17:52.589 foundational agreements. You know, not all of 00:17:52.589 --> 00:17:54.529 them came to fruition, like the initial insulin 00:17:54.529 --> 00:17:56.529 integration, which was later discontinued in 00:17:56.529 --> 00:17:59.170 2013. But which partnerships really revealed 00:17:59.170 --> 00:18:01.390 their desire for market diversification early 00:18:01.390 --> 00:18:03.890 on? I think the most surprising agreement from 00:18:03.890 --> 00:18:06.990 2008 was the development partnership with Edwards 00:18:06.990 --> 00:18:09.529 Life Sciences. Edwards Life Sciences. OK. This 00:18:09.529 --> 00:18:12.390 wasn't focused on consumer chronic care. It was 00:18:12.390 --> 00:18:15.730 for a CGM specifically designed for the intensive 00:18:15.730 --> 00:18:18.349 care unit, the ICU hospital environment. Wait, 00:18:18.410 --> 00:18:22.049 a hospital grade critical care CGM. That is far 00:18:22.049 --> 00:18:24.549 outside the traditional consumer diabetes management 00:18:24.549 --> 00:18:27.329 bubble. What does targeting the ICU... ICU tell 00:18:27.329 --> 00:18:29.450 us about their broader vision even back then? 00:18:29.609 --> 00:18:32.049 It shows they saw the utility of continuous monitoring 00:18:32.049 --> 00:18:35.009 extending beyond chronic disease and into broader 00:18:35.009 --> 00:18:38.250 critical care settings. Maintaining tight glycemic 00:18:38.250 --> 00:18:40.730 control blood sugar management is crucial in 00:18:40.730 --> 00:18:42.750 high stress critical illness situations in the 00:18:42.750 --> 00:18:45.630 ICU. Even for non -diabetic patients, right? 00:18:45.809 --> 00:18:48.750 Often, yes. Poor control can really impact recovery 00:18:48.750 --> 00:18:51.299 and mortality. A dedicated, highly accurate, 00:18:51.460 --> 00:18:54.119 hospital -grade CGM was a major strategic goal, 00:18:54.279 --> 00:18:57.039 signaling a very early desire for market diversification 00:18:57.039 --> 00:18:59.740 into clinical infrastructure. But the real revolution, 00:19:00.039 --> 00:19:02.299 the one that fundamentally changed the daily 00:19:02.299 --> 00:19:04.440 lives of millions of people with type 1 diabetes, 00:19:04.799 --> 00:19:08.119 was the closed -loop insulin revolution. Absolutely. 00:19:08.180 --> 00:19:10.960 And this required securing those critical, non 00:19:10.960 --> 00:19:13.460 -exclusive agreements with major pump manufacturers, 00:19:13.859 --> 00:19:16.660 leveraging that G6 interoperability designation 00:19:16.660 --> 00:19:19.019 we just talked about. This is where the story 00:19:19.109 --> 00:19:22.569 of their strategic genius really emerges. The 00:19:22.569 --> 00:19:24.710 decision to make their partnerships non -exclusive 00:19:24.710 --> 00:19:27.750 was just paramount. They didn't bet on one pump 00:19:27.750 --> 00:19:30.009 winning the market. They decided to become the 00:19:30.009 --> 00:19:32.329 foundational data layer for every major player. 00:19:32.509 --> 00:19:35.170 The first major partnership in this realm was 00:19:35.170 --> 00:19:38.130 announced in 2015 with Tandem Diabetes Care. 00:19:38.460 --> 00:19:40.440 Right. And this non -exclusive agreement was 00:19:40.440 --> 00:19:43.460 designed to integrate Dexcom's G5 and G6 systems 00:19:43.460 --> 00:19:47.180 directly into Tandem's insulin pumps. This laid 00:19:47.180 --> 00:19:49.680 all the groundwork. It did. And that collaboration 00:19:49.680 --> 00:19:52.640 culminated four years later in December 2019 00:19:52.640 --> 00:19:56.299 with the FDA approval of Control IQ. So for our 00:19:56.299 --> 00:19:58.400 learner, let's elaborate on Control IQ. What 00:19:58.400 --> 00:20:00.759 exactly is this technology and why is it rightly 00:20:00.759 --> 00:20:03.339 hailed as a revolutionary artificial pancreas 00:20:03.339 --> 00:20:06.099 system? Control IQ is the ultimate expression 00:20:06.099 --> 00:20:09.400 of the closed loop concept. It uses the tandem 00:20:09.400 --> 00:20:12.799 T .Slim X2 pump in conjunction with the real 00:20:12.799 --> 00:20:15.599 -time, highly accurate data streaming from the 00:20:15.599 --> 00:20:18.380 Dexcom G6 sensor. But the system doesn't just 00:20:18.380 --> 00:20:20.950 react to current. glucose readings, right? It's 00:20:20.950 --> 00:20:23.569 predictive. That's the key. It uses predictive 00:20:23.569 --> 00:20:26.230 algorithms to anticipate where your glucose level 00:20:26.230 --> 00:20:28.450 is going over the next hour. So it's managing 00:20:28.450 --> 00:20:31.349 basal insulin delivery predictively. Precisely. 00:20:31.529 --> 00:20:34.160 Based on the G6 data, And the predictive model, 00:20:34.319 --> 00:20:36.859 control IQ can automatically increase basal insulin 00:20:36.859 --> 00:20:39.819 to preempt high sugar spikes, decrease basal 00:20:39.819 --> 00:20:42.700 delivery, or critically stop insulin delivery 00:20:42.700 --> 00:20:46.339 entirely if a severe low or hypoglycemia is predicted. 00:20:46.539 --> 00:20:49.359 Which significantly reduces the massive cognitive 00:20:49.359 --> 00:20:51.859 and emotional burden of managing type 1 diabetes. 00:20:52.829 --> 00:20:54.990 You're removing so much of the manual calculation, 00:20:55.309 --> 00:20:57.549 the guesswork, and perhaps most importantly, 00:20:57.650 --> 00:21:00.549 the intense fear of severe lows, especially overnight. 00:21:00.789 --> 00:21:03.369 It moves management from reactive to truly automated 00:21:03.369 --> 00:21:05.789 and predictive. And the clinical data from the 00:21:05.789 --> 00:21:07.549 trials supporting it showed measurable improvements 00:21:07.549 --> 00:21:09.650 in time and range metrics and A1C reductions. 00:21:10.009 --> 00:21:13.670 But the qualitative impact, better sleep, reduced 00:21:13.670 --> 00:21:17.589 anxiety, fewer severe hypoglycemic events, that's 00:21:17.589 --> 00:21:19.490 what truly defines its revolutionary nature. 00:21:19.690 --> 00:21:22.759 Without doubt. But Tandem only serves the tubed 00:21:22.759 --> 00:21:25.599 pump market. So Dexcom realized they needed to 00:21:25.599 --> 00:21:27.859 secure the tubeless market as well to ensure 00:21:27.859 --> 00:21:31.119 total dominance. They did. In February 2020, 00:21:31.420 --> 00:21:33.420 they completed the circle by signing a global, 00:21:33.559 --> 00:21:36.180 non -exclusive agreement with Insulate Corporation. 00:21:36.829 --> 00:21:38.809 And this partnership was strategically vital, 00:21:38.990 --> 00:21:42.150 aiming to combine current and future Dexcom CGMs 00:21:42.150 --> 00:21:44.890 with Insulet's tubeless insulin delivery pod, 00:21:45.130 --> 00:21:48.089 the Omnipod Horizon system. Right. So this ensures 00:21:48.089 --> 00:21:49.890 that regardless of whether a patient prefers 00:21:49.890 --> 00:21:52.549 a tubed pump or a highly discrete tubeless patch 00:21:52.549 --> 00:21:55.589 pump, Dexcom's data remains the critical engine 00:21:55.589 --> 00:21:57.750 powering the automation. It's brilliant. And 00:21:57.750 --> 00:21:59.529 the integration with Insulet was comprehensive, 00:21:59.829 --> 00:22:03.150 not just a simple beta feed. It allowed for automated 00:22:03.150 --> 00:22:05.589 insulin dosing adjustments based on Insulet's 00:22:05.589 --> 00:22:08.029 proprietary data. algorithm and, importantly, 00:22:08.309 --> 00:22:10.650 allowed for control and dosing adjustments via 00:22:10.650 --> 00:22:13.009 a smartphone app. Which consolidates monitoring, 00:22:13.269 --> 00:22:15.769 dosing, and control into a highly consumer -friendly 00:22:15.769 --> 00:22:18.309 piece of technology. So moving beyond the physical 00:22:18.309 --> 00:22:21.309 insulin delivery devices, Dexcom also aggressively 00:22:21.309 --> 00:22:23.470 pursued partnerships in the digital health sphere. 00:22:23.690 --> 00:22:25.710 They weren't just satisfied with controlling 00:22:25.710 --> 00:22:27.750 the hardware, they wanted to ensure their data 00:22:27.750 --> 00:22:30.130 flowed into every major chronic care management 00:22:30.130 --> 00:22:32.869 platform. And this strategy highlights how data 00:22:32.869 --> 00:22:35.089 integration expands their reach and utility. 00:22:35.880 --> 00:22:39.160 far beyond just selling a sensor. A key partnership 00:22:39.160 --> 00:22:42.980 in June 2019 was with Companion Medical. They 00:22:42.980 --> 00:22:45.940 collaborated to exchange CGM data from the Dexcom 00:22:45.940 --> 00:22:48.019 platform with the insulin dose data captured 00:22:48.019 --> 00:22:50.859 by Companion's InPen, which is a smart insulin 00:22:50.859 --> 00:22:54.079 pen. Right. And merging those two specific data 00:22:54.079 --> 00:22:57.079 streams, CGM and dosing history, why is that 00:22:57.079 --> 00:22:59.500 so important? Well, because it creates a complete 00:22:59.500 --> 00:23:02.319 picture for the patient and the clinician. By 00:23:02.319 --> 00:23:04.799 routing that combined information into both companies' 00:23:04.880 --> 00:23:07.259 software applications, the physician can see 00:23:07.259 --> 00:23:09.759 not only the patient's glucose level, but precisely 00:23:09.759 --> 00:23:12.099 when they took their last dose, how much they 00:23:12.099 --> 00:23:14.380 took, and what that dosage did to their subsequent 00:23:14.380 --> 00:23:16.980 glucose trend. It vastly improves the quality 00:23:16.980 --> 00:23:19.200 of clinical decision making. For sure. And then 00:23:19.200 --> 00:23:21.180 they connected with larger digital chronic care 00:23:21.180 --> 00:23:24.750 management giants in 2020. Two major moves emphasized 00:23:24.750 --> 00:23:28.670 this data -centric focus. In January 2020, they 00:23:28.670 --> 00:23:31.150 partnered with Livongo, a prominent digital chronic 00:23:31.150 --> 00:23:35.109 care company. The goal was to share G6 data seamlessly 00:23:35.109 --> 00:23:38.599 with Livongo's platform. So Livongo could incorporate 00:23:38.599 --> 00:23:41.880 CGM data alongside other patient data like blood 00:23:41.880 --> 00:23:44.559 pressure, weight, activity, creating a genuinely 00:23:44.559 --> 00:23:47.680 holistic view of the patient. Exactly. And then 00:23:47.680 --> 00:23:49.559 quickly following that, they partnered with WellDoc. 00:23:49.640 --> 00:23:52.420 That March 2020 partnership integrated G6 data 00:23:52.420 --> 00:23:55.259 with Bluestar, which is another significant FDA 00:23:55.259 --> 00:23:57.500 cleared digital platform for diabetes management. 00:23:57.779 --> 00:23:59.740 The critical takeaway from this trio of digital 00:23:59.740 --> 00:24:02.700 partnerships is Dexcom's relentless focus on 00:24:02.700 --> 00:24:05.750 ubiquitous data accessibility. They wanted to 00:24:05.750 --> 00:24:07.670 ensure that no matter what digital tools the 00:24:07.670 --> 00:24:10.190 provider was using, the G6 data would be the 00:24:10.190 --> 00:24:12.710 essential, readily accessible, and actionable 00:24:12.710 --> 00:24:15.049 foundation within those platforms. The final 00:24:15.049 --> 00:24:16.930 and perhaps most forward -looking partnership 00:24:16.930 --> 00:24:19.509 revealed in our sources completely moves away 00:24:19.509 --> 00:24:21.410 from traditional clinical diabetes management 00:24:21.410 --> 00:24:23.849 and into consumer wellness and lifestyle tracking. 00:24:24.109 --> 00:24:26.710 That is the Strategic Partnership and Data Exchange 00:24:26.710 --> 00:24:31.410 announced with Aura in November 2024. This signals 00:24:31.410 --> 00:24:34.789 a formal, calculated integration beyond specialized 00:24:34.789 --> 00:24:37.809 medical devices and into broader consumer health 00:24:37.809 --> 00:24:40.410 platforms. Specifically, sophisticated wearable 00:24:40.410 --> 00:24:42.829 technology that tracks sleep quality, activity, 00:24:42.990 --> 00:24:45.970 and recovery metrics. Exactly. So if you connect 00:24:45.970 --> 00:24:48.009 the Aura partnership with the recent launch of 00:24:48.009 --> 00:24:51.430 the OTC product, Stilo, the strategic move becomes 00:24:51.430 --> 00:24:54.390 incredibly clear. They are proactively building 00:24:54.390 --> 00:24:57.190 a bridge between clinical -grade monitoring and 00:24:57.190 --> 00:24:59.470 the lucrative world of metabolic wellness tracking. 00:25:00.079 --> 00:25:02.720 It's the ultimate convergence play. It recognizes 00:25:02.720 --> 00:25:05.079 that continuous glucose data is valuable not 00:25:05.079 --> 00:25:07.640 just for managing a diagnosed disease, but for 00:25:07.640 --> 00:25:10.240 optimizing performance, fueling athletic recovery, 00:25:10.440 --> 00:25:12.779 and informing general metabolic health choices 00:25:12.779 --> 00:25:15.240 for the non -diabetic consumer. By partnering 00:25:15.240 --> 00:25:17.839 with a significant player like Ora, they legitimize 00:25:17.839 --> 00:25:20.759 the use of CGM data in that wellness space. A 00:25:20.759 --> 00:25:23.640 very, very smart move. So, to understand where 00:25:23.640 --> 00:25:26.119 Dexcom is positioned for the next decade, we 00:25:26.119 --> 00:25:29.349 need to look at two critical areas. the major 00:25:29.349 --> 00:25:31.829 R &D partnerships that drove their latest innovation, 00:25:32.069 --> 00:25:34.369 and where they are putting their investment dollars 00:25:34.369 --> 00:25:36.890 through their venture arms. Let's start with 00:25:36.890 --> 00:25:39.410 that crucial Google connection. The development 00:25:39.410 --> 00:25:42.470 of the G7, most accurate device to date, was 00:25:42.470 --> 00:25:45.970 not purely an internal engineering feat. Dexcom 00:25:45.970 --> 00:25:48.210 strategically partnered with Google Life Sciences, 00:25:48.490 --> 00:25:51.529 which subsequently rebranded as Verily back in 00:25:51.529 --> 00:25:55.190 2015, specifically to develop the Dexcom G7 platform. 00:25:55.599 --> 00:25:58.319 Now, why couldn't Dexcom, with all its billions 00:25:58.319 --> 00:26:01.019 in revenue, handle the G7 development internally? 00:26:01.460 --> 00:26:04.539 What did a colossal tech player like Google or 00:26:04.539 --> 00:26:06.819 Verily bring to the table that was so indispensable? 00:26:07.259 --> 00:26:09.380 I think it highlights the sheer scientific and 00:26:09.380 --> 00:26:11.400 computational muscle required to create these 00:26:11.400 --> 00:26:14.500 next generation devices. The G7 required incredible 00:26:14.500 --> 00:26:17.779 advances in miniaturization. It's smaller, thinner. 00:26:17.920 --> 00:26:20.549 It needs a much smaller inserted filament. all 00:26:20.549 --> 00:26:22.849 while maintaining superior accuracy. So Google 00:26:22.849 --> 00:26:25.269 verily brought expertise in miniature electronics 00:26:25.269 --> 00:26:28.470 fabrication. That, and advanced data analytics, 00:26:28.750 --> 00:26:31.490 machine learning for refining sensor algorithms, 00:26:31.769 --> 00:26:34.450 and perhaps even non -traditional sensor technology 00:26:34.450 --> 00:26:37.650 research. So essentially, they accessed a Silicon 00:26:37.650 --> 00:26:39.809 Valley level of engineering precision and data 00:26:39.809 --> 00:26:42.890 science that accelerated the G7's journey to 00:26:42.890 --> 00:26:46.130 market and guaranteed its cutting -edge sophistication. 00:26:46.250 --> 00:26:50.529 Exactly. The G7's complexity required input far 00:26:50.529 --> 00:26:52.569 beyond traditional medical device engineering. 00:26:52.890 --> 00:26:55.569 It's a marriage of medtech and big data tech. 00:26:55.730 --> 00:26:57.529 And now let's talk about the company's internal 00:26:57.529 --> 00:26:59.829 investment strategy, which is often a perfect 00:26:59.829 --> 00:27:02.470 map of where they believe the future lies. In 00:27:02.470 --> 00:27:05.789 early 2021, they launched Dexcom Ventures. Their 00:27:05.789 --> 00:27:08.529 dedicated venture capital arm, yes. And when 00:27:08.529 --> 00:27:10.849 a major corporation launches a VC arm, they're 00:27:10.849 --> 00:27:13.509 signaling two things. One, they want to maintain 00:27:13.509 --> 00:27:16.430 market leadership. And two, they want to explore 00:27:16.430 --> 00:27:18.569 adjacent technologies that might disrupt their 00:27:18.569 --> 00:27:20.869 core business before anyone else does. And what's 00:27:20.869 --> 00:27:22.890 fascinating here is the dual strategic focus 00:27:22.890 --> 00:27:25.490 of Dexcom Ventures. It is. The first focus is 00:27:25.490 --> 00:27:28.230 logical and defensive, emerging continuous glucose 00:27:28.230 --> 00:27:30.630 monitoring technologies. Right. Ensuring they 00:27:30.630 --> 00:27:32.970 stay ahead in their core market by funding potential 00:27:32.970 --> 00:27:36.549 future competitors. But the second focus, where 00:27:36.549 --> 00:27:39.589 the true diversification intent lies, is much 00:27:39.589 --> 00:27:42.220 more expansive. The primary investment interest 00:27:42.220 --> 00:27:45.140 is in devices measuring the levels of other types 00:27:45.140 --> 00:27:47.880 of substances in analytes. Let's pause on that 00:27:47.880 --> 00:27:51.119 word, analytes. For our learner, what does this 00:27:51.119 --> 00:27:53.559 actually mean in practical terms? We've been 00:27:53.559 --> 00:27:56.079 talking about glucose. What other substances 00:27:56.079 --> 00:27:58.119 could they be looking to monitor continuously? 00:27:58.640 --> 00:28:01.380 An analyte is simply a substance whose components 00:28:01.380 --> 00:28:04.819 are being measured. So Dexcom has mastered interstitial 00:28:04.819 --> 00:28:07.809 fluid analysis for glucose. They can translate 00:28:07.809 --> 00:28:10.630 that same expertise -making, a sensor that sticks, 00:28:10.829 --> 00:28:13.509 stays accurate, and communicates securely to 00:28:13.509 --> 00:28:15.869 monitor a host of other relevant biomarkers. 00:28:16.190 --> 00:28:18.089 So give us some concrete examples of what they 00:28:18.089 --> 00:28:20.309 might be exploring through Dexcom Ventures. What 00:28:20.309 --> 00:28:22.769 markets would those analytes address? Well, think 00:28:22.769 --> 00:28:25.049 about continuous lactate monitoring for athletes 00:28:25.049 --> 00:28:27.750 or critical care patients, providing real -time 00:28:27.750 --> 00:28:30.109 data on muscle fatigue or circulatory issues. 00:28:30.230 --> 00:28:32.670 Okay. Or continuous cortisol monitoring, which 00:28:32.670 --> 00:28:35.569 tracks stress hormones, a massive market in wellness 00:28:35.569 --> 00:28:37.650 and mental health management. They could be looking 00:28:37.650 --> 00:28:40.170 at continuous hydration monitoring, which is 00:28:40.170 --> 00:28:42.940 critical for the elderly. or for high -end endurance 00:28:42.940 --> 00:28:45.619 athletes. They could even potentially monitor 00:28:45.619 --> 00:28:48.440 inflammation markers or essential electrolytes. 00:28:48.579 --> 00:28:51.680 That opens up massive potential markets. It suggests 00:28:51.680 --> 00:28:54.599 they want to translate their core expertise in 00:28:54.599 --> 00:28:57.900 accurate, miniaturized, continuous glucose sensing 00:28:57.900 --> 00:29:01.339 into a continuous general physiological sensing 00:29:01.339 --> 00:29:04.079 platform. This is the definition of moving from 00:29:04.079 --> 00:29:07.019 a diabetes company to a general continuous health 00:29:07.019 --> 00:29:09.640 monitoring company. And we also see a secondary 00:29:09.640 --> 00:29:12.779 but absolutely crucial area of investment for 00:29:12.779 --> 00:29:15.599 Dexcom Ventures. Cybersecurity platforms. Yes. 00:29:15.640 --> 00:29:17.940 Specifically designed for the software used in 00:29:17.940 --> 00:29:20.380 medical devices. Now, investing in cybersecurity 00:29:20.380 --> 00:29:22.839 for their own ecosystem seems like a necessary 00:29:22.839 --> 00:29:26.160 cost, not a venture strategy. Why list it as 00:29:26.160 --> 00:29:28.500 a strategic investment? Because it acknowledges 00:29:28.500 --> 00:29:30.900 the profound digital risk inherent in running 00:29:30.900 --> 00:29:33.319 a connected healthcare ecosystem, especially 00:29:33.319 --> 00:29:35.619 one where the hardware automatically controls 00:29:35.619 --> 00:29:38.160 insulin delivery. If a connected pump or sensor 00:29:38.160 --> 00:29:40.279 system were ever compromised, the implications 00:29:40.279 --> 00:29:44.700 could Exactly. Therefore, investing in proprietary, 00:29:45.019 --> 00:29:47.779 cutting -edge cybersecurity platforms, often 00:29:47.779 --> 00:29:50.480 by funding startups focused on this niche, is 00:29:50.480 --> 00:29:52.740 a necessary investment to sustain the entire 00:29:52.740 --> 00:29:56.359 automated ecosystem. Security is not an afterthought. 00:29:56.480 --> 00:29:59.240 It's a non -negotiable component of running a 00:29:59.240 --> 00:30:01.869 life -critical technology platform. So let's 00:30:01.869 --> 00:30:03.750 circle back to the strategic importance of the 00:30:03.750 --> 00:30:05.549 Stello over -the -counter device, which Time 00:30:05.549 --> 00:30:07.769 magazine recognized as one of the best inventions 00:30:07.769 --> 00:30:10.869 of 2024. Considering all these partnerships and 00:30:10.869 --> 00:30:13.750 the venture focus on new analytes, what does 00:30:13.750 --> 00:30:17.450 the move to OTC truly signify for Dexcom's business 00:30:17.450 --> 00:30:19.950 model? Right. So what does this all mean for 00:30:19.950 --> 00:30:22.829 the big picture? The move to OTC fundamentally 00:30:22.829 --> 00:30:25.819 changes their addressable market. Before STALO, 00:30:25.859 --> 00:30:28.480 Dexcom was largely confined to type 1 patients 00:30:28.480 --> 00:30:31.400 and specific high -risk insulin -using type 2 00:30:31.400 --> 00:30:34.140 patients, a specific clinically defined population 00:30:34.140 --> 00:30:37.009 that required a prescription. With an OTC device, 00:30:37.250 --> 00:30:39.309 they can reach the millions of non -insulin -using 00:30:39.309 --> 00:30:41.710 type 2 patients who still need close monitoring 00:30:41.710 --> 00:30:44.150 for diet and lifestyle management, but who may 00:30:44.150 --> 00:30:46.309 not qualify or want to go through the prescription 00:30:46.309 --> 00:30:49.710 process. And beyond that, it expands the market 00:30:49.710 --> 00:30:52.769 to include that enormous consumer segment engaged 00:30:52.769 --> 00:30:55.670 in proactive metabolic health, wellness, and 00:30:55.670 --> 00:30:58.089 performance optimization. People without a formal 00:30:58.089 --> 00:31:01.069 diabetes diagnosis who simply want the data to 00:31:01.069 --> 00:31:03.670 biohack their nutrition or fitness. So the Stela 00:31:03.670 --> 00:31:06.089 launch, supported by the move into broader sensor 00:31:06.089 --> 00:31:08.569 technology via Dexcom Ventures and partnerships 00:31:08.569 --> 00:31:11.509 like Aura, paints a picture of a company actively 00:31:11.509 --> 00:31:14.109 shifting its identity. From a specialized diabetes 00:31:14.109 --> 00:31:16.829 technology firm to the leading continuous health 00:31:16.829 --> 00:31:19.109 monitoring platform globally. They are essentially 00:31:19.109 --> 00:31:22.089 leveraging their core competence, making a sensor 00:31:22.089 --> 00:31:25.369 stick, and transmit hyper -accurate data to tackle 00:31:25.369 --> 00:31:27.730 a much larger, more diverse, and potentially 00:31:27.730 --> 00:31:30.450 more profitable global health market. And they 00:31:30.450 --> 00:31:32.009 have successfully future -proofed themselves. 00:31:32.430 --> 00:31:35.369 by mastering the interoperability of their data, 00:31:35.490 --> 00:31:37.829 making them the essential engine for almost any 00:31:37.829 --> 00:31:40.130 automated health solution, whether it's high 00:31:40.130 --> 00:31:42.529 -end clinical care or consumer -driven wellness. 00:31:42.789 --> 00:31:45.230 This deep dive really eliminates the layers of 00:31:45.230 --> 00:31:47.589 sophistication and the long -term strategy behind 00:31:47.589 --> 00:31:50.410 Dexcom's success. Let's quickly reiterate the 00:31:50.410 --> 00:31:52.369 three major arcs we've covered today for you, 00:31:52.529 --> 00:31:54.930 the learner. First, we tracked the incredible 00:31:54.930 --> 00:31:57.670 speed of their technological acceleration. They 00:31:57.670 --> 00:31:59.970 went from that cumbersome three -day STS sensor 00:31:59.970 --> 00:32:04.069 in 2006 to the G7 in 2022, achieving superior 00:32:04.069 --> 00:32:06.990 accuracy, miniaturization, and critical features 00:32:06.990 --> 00:32:09.950 like ICGM interoperability and direct mobile 00:32:09.950 --> 00:32:12.720 connection via Bluetooth. in the G5. Second, 00:32:13.019 --> 00:32:16.039 we saw the strategic genius of becoming the central 00:32:16.039 --> 00:32:18.740 data hub for automated insulin delivery systems. 00:32:19.039 --> 00:32:21.460 Their non -exclusive partnerships with giants 00:32:21.460 --> 00:32:24.180 like Tandem and Insulet were crucial, enabling 00:32:24.180 --> 00:32:26.299 automated insulin adjustments through technologies 00:32:26.299 --> 00:32:29.299 like Control IQ, making life safer and vastly 00:32:29.299 --> 00:32:31.519 simpler for millions of users. Right. Removing 00:32:31.519 --> 00:32:33.980 the burden of manual reactive management. And 00:32:33.980 --> 00:32:36.140 finally, we examine the visionary approach of 00:32:36.140 --> 00:32:38.980 their venture capital arm, Dexcom Ventures, which 00:32:38.980 --> 00:32:56.380 is investing not only in necessary areas It's 00:32:56.380 --> 00:32:58.779 a compelling case study in how sustained, well 00:32:58.779 --> 00:33:01.339 -capitalized innovation in a specialized medical 00:33:01.339 --> 00:33:03.880 field can lead to broad, transformative influence 00:33:03.880 --> 00:33:06.319 across the entire spectrum of healthcare technology. 00:33:07.160 --> 00:33:09.339 But as we look at their future focus, particularly 00:33:09.339 --> 00:33:11.640 that in investment in measuring other substances, 00:33:12.119 --> 00:33:15.000 it raises a profoundly provocative question for 00:33:15.000 --> 00:33:18.339 you to mull over. Indeed. Given that Dexcom Ventures 00:33:18.339 --> 00:33:20.420 is actively investing in sensors that measure 00:33:20.970 --> 00:33:23.690 other types of substances in analytes, and considering 00:33:23.690 --> 00:33:25.710 their strategic move to integrate with broader 00:33:25.710 --> 00:33:28.210 consumer platforms like Aura for data exchange, 00:33:28.529 --> 00:33:31.609 a platform focused on sleep and recovery, what 00:33:31.609 --> 00:33:34.609 specific broader chronic health conditions beyond 00:33:34.609 --> 00:33:37.730 just diabetes might these newly integrated, highly 00:33:37.730 --> 00:33:40.529 accurate continuous monitoring systems be designed 00:33:40.529 --> 00:33:43.230 to tackle next? Think about the data. If they 00:33:43.230 --> 00:33:45.289 can continuously monitor stress markers like 00:33:45.289 --> 00:33:48.049 cortisol or specific inflammation markers or 00:33:48.049 --> 00:33:50.539 hydration levels with clinical accuracy, they 00:33:50.539 --> 00:33:52.279 move into preemptive chronic disease management 00:33:52.279 --> 00:33:54.519 for conditions like kidney disease, cardiovascular 00:33:54.519 --> 00:33:57.119 risk, or even neurological disorders linked to 00:33:57.119 --> 00:34:00.039 inflammation. The technology has proven the only 00:34:00.039 --> 00:34:02.680 limit now is which essential analyte they choose 00:34:02.680 --> 00:34:05.019 to conquer next and how that integrates into 00:34:05.019 --> 00:34:07.819 our daily wearables. That level of personalized 00:34:07.819 --> 00:34:11.019 predictive health data promises to revolutionize 00:34:11.019 --> 00:34:13.519 how we approach aging and wellness. And that's 00:34:13.519 --> 00:34:15.829 subject for a deep dive all its own. For now, 00:34:15.849 --> 00:34:17.949 that's all we have time for. Thank you for joining 00:34:17.949 --> 00:34:20.449 us on the Deep Dive. We hope you feel significantly 00:34:20.449 --> 00:34:23.150 more well -informed about the complex ecosystem 00:34:23.150 --> 00:34:26.110 powering modern continuous glucose monitoring. 00:34:26.429 --> 00:34:28.230 Until next time, keep learning.